Securities And Exchange Commission

Latest Headlines

Latest Headlines

More insider trading charges from Sanofi's Chattem buyout

On Tuesday, the SEC filed civil complaints against two brothers accused of buying stock based on secret knowledge of the then-upcoming takeover--the 8th case the Commission has brought against insider trading connected to that deal, it says.

SEC probes former Dendreon CEO's stock sales

The Securities and Exchange Commission's insider trading team has Dendreon under a microscope. The agency has launched a civil investigation into stock trades by former CEO Mitchell Gold to see whether he acted on inside information about disappointing Provenge sales.

UPDATED: Affymax, Takeda pull Omontys after 3 deaths

Severe hypersensitivity reactions in Omontys patients prompted Affymax and Takeda Pharmaceutical to recall all lots of the anemia drug, designed for use in dialysis patients.

Novartis faces probes on Tekturna tactics, Iran sales

Novartis may be looking at another trial of its troubled blood pressure drug Tekturna. This would not be a clinical trial, however, but more of the civil or criminal kind.

Icahn slams Forest for undisclosed FDA warning

On the eve of Forest Laboratories' proxy vote, activist investor Carl Icahn is still campaigning. After accusing Forest's board of cronyism and lethargy, after critiquing CEO Howard Solomon's performance--and his son's résumé--Icahn is taking the company to task for a recent FDA warning letter.

Did Stiefel undervalue employee shares before GSK buyout?

Was something rotten in Stiefel Laboratories ' dealings with employee-shareholders before its sale to GlaxoSmithKline ($GSK)? The Securities and Exchange Commission believes so. The U.S. agency

SEC accuses ex-Stiefel CEO of fraud

When he sold his company Stiefel Laboratories to GlaxoSmithKline ($GSK) in 2009, Charles Stiefel appeared to be a lucky man. But now, roughly two years later, the Securities and Exchange Commission

Elan accuses rebel director of insider trading

In an unusual twist to a boardroom spat at Elan, the Irish drugmaker has reported one of its own directors to the U.S. Securities and Exchange Commission for potential insider-trading allegations.

Feds probe Merck in FCPA enforcement push

Merck (NYSE: MRK) has been roped into a federal probe of pharma's foreign operations. The Justice Department and Securities and Exchange Commission are investigating the drugmaker for Foreign Corrupt

SEC investigating Mylan investor confab

Did Mylan divulge confidential information to some selected investors last fall? The Securities and Exchange Commission wants to know. The regulator has asked several investment banks about a